Small fiber neuropathy:

CNS inflammation after COVID-19 mRNA vaccination: a case series


General Neuro side effects:

18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer:

3 cases of Tinnitus following mRNA vaccination:

Tinnitus/Hearing Disturbances:

Severe dyskinesia in Parkinson Patient following mRNA vaccination:

Two cases of encephalopathy and seizures following Moderna:

Acute disseminated encephalitis following Pfizer:

Postvaccinal encephalitis following AstraZeneca:

Acute encephalitis, myoclonus, and sweet syndrome after mRNA vaccine:

Aseptic Meningitis following Pfizer:

Tinnitus/cochleopathy following AstraZeneca:

Trigeminal Neuralgia and cervical radiculitis after Pfizer:

Amyotrophic neuralgia secondary to AstraZeneca:

Neuralgic amyotrophy following mRNA vaccination: Gravis Flare Following Moderna:

Acute Myelitis following AstraZeneca:

Facial Palsy: cmab068/6311086

Bilateral facial weakness with paresthesia variant of GBS following AstraZeneca:

Facial Weakness, extremity weakness, encephalopathy, and severe refractory ITP following Moderna:

Facial Palsy:…/10.1093/fampra/cmab068/6311086

36yo with Bells Palsy, left arm tingling/numbness/weakness following mRNA vaccination:

50yoM with Bells Palsy after Pfizer, ongoing symptoms after 21 days:

21yoF nurse with Bells Palsy following Pfizer:

61yoM with Bells Palsy after each dose of Pfizer:

57yoF with Bells Palsy <36 hours after 2nd dose of Pfizer:

34yoF with Bells Palsy 2 days after Moderna:

Bells Palsy following mRNA and inactivated (CoronaVac) vaccines: a case series and nested Case-Control study:

2 cases of Sensory GBS following AstraZeneca:

GBS following Johnson and Johnson:

4 cases of GBS following Astra Zeneca:

GBS in elderly gentleman following 2nd dose of Pfizer:

GBS following Pfizer:

GBS after the first dose of Pfizer:

GBS in a 25 yoF following 2nd dose of Pfizer:

GBS 10 days after AstraZeneca:

GBS 11 days after AstraZeneca:

GBS following AstraZeneca:

7 cases of GBS following AstraZeneca:

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine:

Patient’s first MS Flare following Pfizer:

MS Flare following AZ:

2 cases of Parsonage Turner Syndrome following Moderna and Pfizer:

Transient akathisia after Pfizer:


Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination:

Neuromyelitis optica spectrum disorder (NMOSD):

Cytotoxic lesion of the Corpus Callousum following mRNA vaccination:

Headache after AstraZeneca: a MultiCenter observational cohort center:

Worsening Neuro-Oncologic Disease Symptoms following mRNA vaccination:

Clinical characteristics of Headache following Pfizer, a multicenter observational cohort study:

CVA and Thrombocytopenia following Astrazeneca:

Cerebral venous sinus thrombosis after AstraZeneca, neurologic and radiological management:

Cerebral Venous sinus thrombosis, review of European cases:

45 cases of Cerebral Venous thrombosis:

Review of European data of Cerebral venous thrombosis with cytopenia, observed in Pfizer, Moderna, and AstraZeneca

New onset psychosis after mRNA vaccine:

Delirium in an elderly patient following vaccination:

Delirium in an elderly patient following Pfizer:

Neuro Autoimmune –